Preliminary Results of Prophylactic Tocilizumab After Axicabtagene Ciloleucel (axi-cel; KTE-C19) Treatment for Patients with Relapsed/Refractory, Aggressive NHL

JHOP - March 2018 Vol 8, No 1 - CLL & Other B-Cell Malignancies - ASH 2017

 

ZUMA-1 is a pivotal, multicenter trial of axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients with refractory, aggressive non-Hodgkin lymphoma (NHL).1 The objective response rate (ORR) was 82% with a 54% rate of complete response (CR), and 44% of responses were ongoing at the time of the primary analysis.2 Grade ≥3 cytokine release syndrome (CRS) and neurologic events (NEs) occurred in 13% and 28% of patients, respectively.

At ASH 2017, the authors presented the results of a safety management study (SMS) that was added to ZUMA-1 to further characterize mechanisms underlying CRS and NEs associated with CAR T-cell therapy. The SMS was also designed to evaluate the impact of prophylactic use of tocilizumab and levetiracetam on the rates of these adverse events (AEs).3

In the SMS, patients with relapsed or refractory transplant-ineligible NHL received low-dose conditioning of 500 mg/m2 of cyclophosphamide and 30 mg/m2 of fludarabine for 3 days, followed by axi-cel at a target dose of 2 × 106 CAR T-cells/kg. Patients also received prophylactic treatment with 750 mg of levetiracetam twice daily on day 0, and 8 mg/kg of tocilizumab on day 2 after axi-cel infusion. A total of 34 patients were included in the SMS analysis (59% had stage III-IV disease, 74% were refractory to ≥second-line therapy, and 24% relapsed ≤12 months after autologous stem-cell transplant).

Most patients in the SMS experienced at least 1 grade ≥3 AE. The most common grade ≥3 AEs were neutropenia/decreased neutrophil count (74%), anemia (50%), thrombocytopenia/decreased platelet count (50%), leukopenia/decreased white blood cell count (32%), febrile neutropenia (29%), encephalopathy (26%), and hypotension (24%). One patient experienced grade 4 CRS, while grade 3 and 4 NEs occurred in 1 patient each. There was 1 death due to AEs: a patient died of cerebral edema.

Among the 34 patients in the SMS, the preliminary ORR was 62%, including a CR rate of 44%. Follow-up duration, however, is currently limited.

The authors concluded that tocilizumab use on day 2 may reduce the incidence of severe CRS but not the incidence of severe NEs in patients treated with CAR T-cell therapy. These data provide evidence that the underlying pathophysiology of NE differs from that of CRS, which may help to further improve the benefit‒risk profile for CAR T-cell therapy.


References

  1. Locke FL, et al. Mol Ther. 2017;25:285-295.
  2. Locke FL, et al. AACR 2017. Abstract 9986.
  3. Locke FL, et al. ASH 2017. Abstract 1547.
Related Items
Phase 2 Study of Brentuximab Vedotin plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
JHOP - March 2018 Vol 8, No 1 published on March 1, 2018 in CLL & Other B-Cell Malignancies - ASH 2017
Median 3.5-Year Follow-Up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle-Cell Lymphoma: A Pooled Analysis
JHOP - March 2018 Vol 8, No 1 published on March 1, 2018 in CLL & Other B-Cell Malignancies - ASH 2017
Adverse Events, Resource Use, and Economic Burden in Patients with Mantle-Cell Lymphoma in the United States
JHOP - March 2018 Vol 8, No 1 published on March 1, 2018 in CLL & Other B-Cell Malignancies - ASH 2017
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
JHOP - March 2018 Vol 8, No 1 published on March 1, 2018 in CLL & Other B-Cell Malignancies - ASH 2017
Last modified: April 12, 2018